PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
作者： Mikaël Croyal , Thi-Thu-Trang Tran , Rose Hélène Blanchard , Jean-Christophe Le Bail , Elise F. Villard
DOI: 10.1042/CS20180040
关键词:
摘要: Therapeutic antibodies targeting proprotein convertase subtilisin kexin type 9 (PCSK9) (eg alirocumab) lower low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] …
portlandpress.com
clinsci.org
researchgate.net 参考文章(25)
Evan A. Stein, Narimon Honarpour, Scott M. Wasserman, Feng Xu, Rob Scott, Frederick J. Raal, Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia Circulation. ,vol. 128, pp. 2113- 2120 ,(2013) , 10.1161/CIRCULATIONAHA.113.004678
Fatiha Nassir, Denise K. Bonen, Nicholas O. Davidson, Apolipoprotein(a) Synthesis and Secretion from Hepatoma Cells Is Coupled to Triglyceride Synthesis and Secretion Journal of Biological Chemistry. ,vol. 273, pp. 17793- 17800 ,(1998) , 10.1074/JBC.273.28.17793
F. Kronenberg, G. Utermann, Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine. ,vol. 273, pp. 6- 30 ,(2013) , 10.1111/J.1365-2796.2012.02592.X
Gilles Lambert, Anne-Laure Jarnoux, Thierry Pineau, Olivier Pape, Maud Chetiveaux, Christian Laboisse, Michel Krempf, Philippe Costet, Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology. ,vol. 147, pp. 4985- 4995 ,(2006) , 10.1210/EN.2006-0098
A. David Marais, Jae B. Kim, Scott M. Wasserman, Gilles Lambert, PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels Pharmacology & Therapeutics. ,vol. 145, pp. 58- 66 ,(2015) , 10.1016/J.PHARMTHERA.2014.07.004
Rocco Romagnuolo, Corey A. Scipione, Michael B. Boffa, Santica M. Marcovina, Nabil G. Seidah, Marlys L. Koschinsky, Lipoprotein(a) Catabolism is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 Through the Low Density Lipoprotein Receptor Journal of Biological Chemistry. ,vol. 290, pp. 11649- 11662 ,(2015) , 10.1074/JBC.M114.611988
Daniel A. Blasiole, Angie T. Oler, Alan D. Attie, Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB Journal of Biological Chemistry. ,vol. 283, pp. 11374- 11381 ,(2008) , 10.1074/JBC.M710457200
Byambaa Enkhmaa, Adnan Abbuthalha, Erdembileg Anuurad, Wei Zhang, Alice F. Tarantal, Lars Berglund, Rhesus monkey (Macaca mulatta) lipoprotein(a) and apolipoprotein(a): high frequency of small size apolipoprotein(a) isoforms. Journal of Medical Primatology. ,vol. 44, pp. 117- 124 ,(2015) , 10.1111/JMP.12160
Maurizio Averna, Santica M. Marcovina, Davide Noto, Thomas G. Cole, Elaine S. Krul, Gustav Schonfeld, Familial Hypobetalipoproteinemia Is Not Associated With Low Levels of Lipoprotein(a) Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 15, pp. 2165- 2175 ,(1995) , 10.1161/01.ATV.15.12.2165
Hagai Tavori, Ilaria Giunzioni, MacRae F. Linton, Sergio Fazio, Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis Circulation Research. ,vol. 113, pp. 1290- 1295 ,(2013) , 10.1161/CIRCRESAHA.113.302655